Medical technology company BioSig Technologies (NASDAQ: BSGM) stock has fallen 45% on Monday after issues with a trial being conducted by its majority-owned subsidiary ViralClear Pharmaceuticals.
BioSig announced that it is halting its Phase 2 trial for its meriemepodib coronavirus treatment in combination with remdesivir.
“The Safety Monitoring Committee (SMC) was unblinded for safety reasons since these patients are at higher risk for dying from their disease,” the company said in a statement.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
ViralClear recently expanded the trial from 40 to 80 hospitalised COVID-19 patients after the implementation of a protocol amendment.
At the time of the review, 44 patients had been enrolled in the study, with 42 receiving the drug.
“This most recent review of the data documented all 22 Grade 4 patients were discharged from the hospital and did not relapse during the 37 day follow-up period,” the BioSig statement read.
“However, patients who were NIAID Grade 3 patients (n = 20) at the time of enrollment had markedly different outcomes. Specifically, the unblinded SMC detected an imbalance in survival rates in these NIAID Grade 3 patients between the placebo and merimepodib making it unlikely that the trial would meet its primary safety endpoints.”
The news has seen BioSig’s share price plummet 45% to $2.75 after closing Friday’s session at $5.03.
The company has confirmed it does not intend to further develop merimepodib.
PEOPLE WHO READ THIS ALSO VIEWED:
